Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL-Stop: Stopping Penicillin in Early Rheumatic Heart Disease
NCT07146048Phase 3Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Mar 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of benzylpenicillin in rheumatic heart disease (RHD) (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Presence of echocardiographic progression of RHD at 2 years. Started Mar 2026; status: recruiting.
02
Drugs
benzylpenicillin
03
Conditions
rheumatic heart disease (RHD)
Beyond the preview
Go deeper on NCT07146048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146048.